Efficacy and immune modulation of KRAS G12C inhibitor sotorasib in murine KRAS G12C mutant non-small cell lung cancers with major co-occurring genomic alterations
Year: 2022
Type: conference-paper
Abstract: Results BackgroundKRAS is the most frequently mutated oncogene in lung cancers, and KRAS G12C is the most frequent mutant isoform in non-small cell lung cancers (NSCLCs).Sotorasib (AMG510) has been approved by FDA in 2021 as the first potent and selective KRAS G12C inhibitor.However, the clinical efficacy of inhibitor monotherapy is curtailed by molecular adaptation and characterized by broad heterogeneity in the depth and duration of individual responses.In addition to their tumor cell-autonomous effects, KRAS G12C inhibitor may also recondition the tumor immune microenvironment (TIME) and synergize with anti-PD-1 therapy to promote tumor regressions and T cell memory.
DOI: 10.52519/00100
Authors: Teng Zhou, Minh Truong Do, Haniel Araujo, Richard Lee, Ferdinandos Skoulidis
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4312256165